Key terms

About VALN

Valneva SE is a specialty vaccine company, which focuses on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. It operates through the following segments: Commercialized Products, COVID, Vaccine Candidates, and Technologies and Services. The Commercialized Products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment develops, manufactures, and distribute related to COVID-19 vaccine candidate, VLA2001. The Vaccine Candidates segment focuses on proprietary research and development programs aiming to generate new approvable products to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies. The Technologies and Services segment offers services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

VALN Financials

1-year income & revenue

Key terms

VALN Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

VALN Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms